Great wrap-up from European Drug Safety & AI 2026 in Barcelona.
It was valuable to engage with industry leaders and peers and share our perspective on the challenges of AI, highlighting the key metrics and evaluation strategy to ensure compliance with regulatory authorities, and to support its transition from concept to real-world application in pharmacovigilance and drug safety.

We had meaningful conversations at the booth, exchanged practical insights, and explored on transitions of AI strategies by the industry.

Thanks to Why Summits for bringing together a strong community and curating thoughtful, high-impact discussions.

Looking forward to continuing these conversations with the ecosystem.